W Clay Gustafson
Overview
Explore the profile of W Clay Gustafson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang J, Jiang L, Maldonato B, Wang Y, Holderfield M, Aronchik I, et al.
Cancer Discov
. 2024 Apr;
14(6):994-1017.
PMID: 38593348
Significance: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition...
2.
Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, et al.
Cell Rep
. 2024 Mar;
43(3):113927.
PMID: 38451815
Neuroblastoma is the most common extracranial solid tumor of childhood. While MYCN and mutant anaplastic lymphoma kinase (ALK) cooperate in tumorigenesis, how ALK contributes to tumor formation remains unclear. Here,...
3.
Morales J, Allegakoen D, Garcia J, Kwong K, Sahu P, Fajardo D, et al.
JCI Insight
. 2022 Oct;
7(23).
PMID: 36282590
Oncogenic FOXO1 gene fusions drive a subset of rhabdomyosarcoma (RMS) with poor survival; to date, these cancer drivers are therapeutically intractable. To identify new therapies for this disease, we undertook...
4.
Yi J, Sias-Garcia O, Nasholm N, Hu X, Iniguez A, Hall M, et al.
Neoplasia
. 2021 Jun;
23(6):624-633.
PMID: 34107377
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription....
5.
Wolpaw A, Bayliss R, Buchel G, Dang C, Eilers M, Gustafson W, et al.
Cancer Res
. 2021 Jan;
81(7):1627-1632.
PMID: 33509943
Effective treatment of pediatric solid tumors has been hampered by the predominance of currently "undruggable" driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of...
6.
Aboian M, Huang S, Hernandez-Pampaloni M, Hawkins R, VanBrocklin H, Huh Y, et al.
J Nucl Med
. 2020 May;
62(1):43-47.
PMID: 32414950
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike I-MIBG, I-MIBG allows high-resolution PET. We evaluated I-MIBG PET/CT for its diagnostic performance...
7.
Koach J, Holien J, Massudi H, Carter D, Ciampa O, Herath M, et al.
Cancer Res
. 2019 Sep;
79(21):5652-5667.
PMID: 31501192
MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and...
8.
Zhang L, He X, Liu X, Zhang F, Huang L, Potter A, et al.
Cancer Cell
. 2019 Sep;
36(3):302-318.e7.
PMID: 31474569
Progenitor heterogeneity and identities underlying tumor initiation and relapse in medulloblastomas remain elusive. Utilizing single-cell transcriptomic analysis, we demonstrated a developmental hierarchy of progenitor pools in Sonic Hedgehog (SHH) medulloblastomas,...
9.
Seo Y, Huh Y, Huang S, Hernandez-Pampaloni J, Hawkins R, Gustafson W, et al.
Med Phys
. 2019 Feb;
46(5):2477-2486.
PMID: 30761545
Purpose: Radiation dose calculated on tumors for radiopharmaceutical therapy varies significantly from tumor to tumor and from patient to patient. Accurate estimation of radiation dose requires multiple time point measurements...
10.
Chen L, Alexe G, Dharia N, Ross L, Iniguez A, Conway A, et al.
J Clin Invest
. 2017 Dec;
128(1):446-462.
PMID: 29202477
Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease...